Delivering innate immune agonists specifically to the right tissue, for the right duration, at the right dose to fight cancer and infectious disease.
+
+
Apros Therapeutics is a drug discovery and development company focused on tissue-targeted small molecule innate immune agonists to increase tumor immunogenicity – turning cold tumors hot. We do this utilizing novel chemistry approaches to precisely target the agonist to certain tumors/tissues with little to no systemic distribution.
TLR agonist have the potential to turn immunologically cold tumors into hot tumors by increasing tumor antigenicity and promoting inflammation within the tumor microenvironment. Combining TLR agonists with checkpoint inhibitors provides complementary mechanisms to boost the tumor immunity cycle and to improve the response of current cancer immune therapies.
Antigen
Processing
& Presentation
Priming & Activation
T Cell Infiltration
Tumor Recognition
Tumor Killing
Antigen Release
Local activation of toll-like receptors affords effective immune priming with minimal systemic inflammation, which is predicted to uncouple efficacy from toxicity. Akin to vaccines, localized innate immune priming leads to systemic adaptive immunity (antibodies and T-cells) against cancer or viral antigens.
Our chemistry-based platform aims to widen the therapeutic window of TLR7 agonists by achieving localized innate immune activation using methods that overcome the limitations of intratumoral injections.
GMP Material Available for Collaboration
Nov 07 2022
Sep 09 2020
Jun 22 2020
Jun 08 2020
Oct 06 2018
Aug 01 2016
